Man Group’s PDS Biotechnology PDSB Stock Holding History

Man Group’s Portfolio PDSB Stock Details PDSB Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2023 Q1	–	Sell	-10,988	Closed	-$89.9K	–	1954
2022 Q4	$145K	Buy	+10,988	New	+$77.5K	﹤0.01%	1833

Other funds holding PDSB

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Two Sigma Advisers New York $51.4B AUM 31.07% 1-Year Est. Return

EWA

EP Wealth Advisors Torrance, California $20.3B AUM

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

LPL Financial San Diego, California $377B AUM 19.32% 1-Year Est. Return

IWA

Inspirion Wealth Advisors Libertyville, Illinois $874M AUM 16.23% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Man Group's PDSB Position: Q1 2023 in Review

Man Group sold out of PDS Biotechnology (PDSB) in Q1 2023, closing a stake of 10,988 shares — an estimated $89.9K sold.

Man Group first reported a position in PDSB in Q4 2022 and held it in 1 quarter. The position peaked at $145K in Q4 2022. 68 funds tracked by Wall St. Rank hold PDSB as of Q1 2023.

Man Group reported no remaining PDS Biotechnology position as of Q1 2023 after selling out during the quarter.
Man Group sold 10,988 PDS Biotechnology shares in Q1 2023, an estimated $89.9K.
Man Group first reported a position in PDS Biotechnology in Q4 2022 and held it in 1 quarter.
Man Group's PDS Biotechnology position peaked at $145K in Q4 2022.
68 funds tracked by Wall St. Rank held PDS Biotechnology as of Q1 2023.

Based on Man Group's 13F filing for Q1 2023, filed 15 May 2023.